Active ingredient

Oclacitinib Maleate

Appearance

This product is a light brown or brown, cross-scored tablet.

Dosage and Administration

Calculated as oclacitinib. Oral administration: For dogs, 0.4 ～ 0.6 mg per 1 kg of body weight, twice a day for 14 consecutive days, and then once a day for maintenance therapy.

Oclacitinib is a synthetic intracellular non-receptor tyrosine kinase (Janus kinase, JAK for short) inhibitor. It inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.

After oral administration to dogs, the drug is absorbed rapidly and well. The feeding status of dogs has no significant effect on the absorption rate or extent.

Following intravenous and oral administration, the terminal half-life appeared similar with absolute bioavailability of 89%, and with low plasma protein binding rate of 66.3%~69.7%. Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative metabolite was identified in plasma and urine. Overall the major clearance route is metabolism with minor contributions from renal and biliary elimination.

As a professional manufacturer of pet diagnosis and treatment products, our company has its own factory and has passed the UR GMP certification. We use automated equipment for production to provide high-quality medicines for your beloved pets.